Parkinson's Drug GT-02287 Shows Durable Positive Phase 1b Data for Gain Therapeutics
GANX sits 32% above its 52-week low of $1.41.
Summary
Gain Therapeutics presented positive interim 150-day data from its Phase 1b study of GT-02287 for Parkinson's disease. The data showed stable and durable MDS-UPDRS scores, a 4.8-point differential in scores for patients with high versus low baseline GluSph, and patient-reported improvements in smell, taste, sleep, and balance/gait. This update builds on previously reported positive clinical data from the same study, reinforcing the drug's potential. For a clinical-stage biotech facing a recent going concern warning, continued positive clinical progress for its lead candidate is critical for investor confidence and future development.
At the time of this announcement, GANX was trading at $1.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.9M. The 52-week trading range was $1.41 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.